Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

Merck's heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other ...

Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry ...

Merck (MRK) on Friday said that the U.S. Food and Drug Administration (FDA) has approved its blockbuster drug Keytruda for the treatment of adult patients with resectable locally advanced head and ...

It boasts more than 80 programs in phase 2 or phase 3 studies. Even with a 25% success rate for these, that should translate ...

Merck MRK boasts more than six blockbuster drugs in its portfolio, with the blockbuster PD-L1 inhibitor Keytruda being the key top-line driver. Keytruda, approved for several types of cancer, alone ...

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat ...

Merck’s (NYSE:MRK) Keytruda is its top selling drug with sales of over $7 billion in 2018. Keytruda is used for the treatment of different types of cancers, including lung, head & neck, and ...

Imfinzi and Keytruda are both prescription drugs that treat certain types of cancer. Learn how their uses, effectiveness, and side effects compare.

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).

Keytruda is a type of immunotherapy medication for treating certain types of cancer. Your doctor can check for signs that Keytruda is working with blood tests, imaging scans, and physical ...

Keytruda (pembrolizumab) is a brand-name IV infusion prescribed to treat many types of cancer, including melanoma and lung cancer. As with other drugs, Keytruda can cause side effects, such as eye ...